You are here
Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Despite improvements in the treatment of CF, physical and emotional support for patients and caregivers is a continuing need. Vertex's Cystic Fibrosis Circle of Care initiative promotes collaboration and provides funding to non-profits that can enhance care and resources for people with CF.
During this year's process, 58 proposals were received from
organizations in 15 countries - a 15 percent increase in total
applicants since last year. Ultimately 18 projects from
The organizations and projects selected met at least one of the following goals:
- Help people with CF live a fuller, more engaged lifestyle;
- Address the psychological and social challenges CF patients face;
- Improve overall support to family and caregivers;
- Provide tools that help CF patients take more ownership of their healthcare needs; and
- Educate CF patients on topics including lifestyle transitions, adherence and navigating new environments.
"We are making tremendous advancements in treating the underlying cause
of cystic fibrosis for many people living with the disease, but our
commitment to CF goes beyond new medicines," said
Grant recipients will present their work at a Circle of Care
One of last year's grant recipients,
"Initiatives like Vertex's
To learn more about Vertex's grants programs, which include substantial
support for medical education, patient education and general charitable
donations, please visit grants.vrtx.com.
Information about our 2017
About Cystic Fibrosis
Cystic fibrosis is a rare, life-threatening genetic disease affecting approximately 75,000 people in North America, Europe and Australia. CF is caused by a defective or missing cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic, or genotyping test, lead to CF by creating non-working or too few CFTR protein at the cell surface. The defective function or absence of CFTR proteins in people with CF results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the mid-to-late 20s.
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and
development sites and commercial offices in the United
States, Europe, Canada and
Europe & Australia, +44 20 3204 5275
News Provided by Acquire Media